多替阿巴拉米片最佳服药时间

As of the end of October 2017, China had reported 746,000 living HIV/AIDS patients and 229,000 reported deaths. The number of people receiving antiviral treatment at the end of 2016 was 495,000. On January 20, GlaxoSmithKline (GSK) announced that its controlled joint venture ViiV Healthcare1's single-pill compound preparation (chemical name: dolutea paramib tablets) with the new generation integrase inhibitor Tevicai (chemical name: dolutegravir) as the core for the treatment of AIDS (HIV) was officially launched in mainland China.

Everyone must be aware of the method of taking Suimeikai (Doteta Abalami Tablets). There is no specific requirement for the taking time of Suimeikan (Dolutea Abalamib Tablets). For adults and adolescents, the recommended dosage of Suimeike (Dolutea Abalamib Tablets) is one tablet each time, once a day. It is best to take it at the same time every day to ensure the continuous effect of the medicine.

If a dose is missed, judge whether to take it again based on the distance to the next dose. If you miss a dose but there are more than 4 hours before the next dose, you should take Suimeike (Doteta abalamib tablets) as soon as possible. If the next dose is less than 4 hours away, the patient should not take the missed dose and wait until the next dose to take it as originally planned. Do not increase the dosage of your medication as this may increase the chance of side effects.

(Dolutegravir, abacavir, or lamivudine) is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines.